AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by The n-BCA Trial Investigators
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by The n-BCA Trial Investigators,

INTERVENTIONAL

N-Butyl Cyanoacrylate Embolization of Cerebral Arteriovenous Malformations: Results of a Prospective, Randomized, Multi-center Trial

The n-BCA Trial Investigators

BACKGROUND AND PURPOSE: Liquid N-butyl cyanoacrylate (n-BCA) use for the treatment of arteriovenous malformations (AVM) in the brain has become part of medical practice. However, no study has led to the Food and Drug Administration’s approval of n-BCA for intravascular use. The purpose of this study was to verify the effectiveness and safety of an n-BCA/Tantalum Powder/Ethiodized Oil mixture, compared with conventional treatment (Trufill polyvinyl alcohol [PVA]) for preoperative embolization of cerebral AVM.

METHODS: Between October 15, 1996, and March 24, 1999, 104 patients at 13 centers were prospectively randomized to undergo embolization using an n-BCA/Tantalum Powder/Ethiodol mixture or Trufill PVA. The pre-embolization therapy goals were determined in terms of the number of pedicles to be embolized and the percent of nidus reduction expected. Embolization results were evaluated by a central laboratory. Subsequent surgical resection data were recorded. Safety evaluation data included recording device complications, procedure complications, and intracranial events/overall neurologic outcomes, which could be either device-related, procedure-related, or both.

RESULTS: The reduction of AVM dimensions (79.4% in the n-BCA group and 86.9% in the PVA group) and the mean number of vessels embolized (2.2 in the n-BCA group and 2.1 in the PVA group) was similar in the two groups. Coils were used more commonly with PVA embolization (P<.0001). No differences were detected in surgical resection time, number of patients who required tranfusion, volume and number of transfusion units, or type and volume of fluid replacement. Glasgow Outcome Scale scores were not significantly different between the two groups before treatment, after embolization, or after resection. Two of 42 patients who underwent resection and had been treated with n-BCA experienced post-resection hematoma, compared with eight of 45 patients who underwent resection and had been treated with PVA (P<.05).

CONCLUSION: This prospective, randomized trial showed that n-BCA is equivalent to PVA as a preoperative embolic agent for treatment of cerebral AVM as determined by percent of nidus reduction and number of feeding pedicles embolized.




This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
E.F. Hauck, B.G. Welch, J.A. White, P.D. Purdy, L.G. Pride, and D. Samson
Preoperative Embolization of Cerebral Arteriovenous Malformations with Onyx
AJNR Am. J. Neuroradiol., March 1, 2009; 30(3): 492 - 495.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
H. Arakawa, Y. Murayama, C.R. Davis, D.L. Howard, W.L. Baumgardner, M.P. Marks, and H.M. Do
Endovascular Embolization of the Swine Rete Mirabile with Eudragit-E 100 Polymer
AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1191 - 1196.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
I. Linfante and A. K. Wakhloo
Brain Aneurysms and Arteriovenous Malformations: Advancements and Emerging Treatments in Endovascular Embolization
Stroke, April 1, 2007; 38(4): 1411 - 1417.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
W. Weber, B. Kis, R. Siekmann, and D. Kuehne
Endovascular Treatment of Intracranial Arteriovenous Malformations with Onyx: Technical Aspects
AJNR Am. J. Neuroradiol., February 1, 2007; 28(2): 371 - 377.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
W.J. van Rooij, M. Sluzewski, and G.N. Beute
Brain AVM Embolization with Onyx
AJNR Am. J. Neuroradiol., January 1, 2007; 28(1): 172 - 177.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
R Al-Shahi and C Warlow
Arteriovenous malformations of the brain: ready to randomise?
J. Neurol. Neurosurg. Psychiatry, October 1, 2005; 76(10): 1327 - 1329.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
R. D. Brown Jr, K. D. Flemming, F. B. Meyer, H. J. Cloft, B. E. Pollock, and M. J. Link
Natural History, Evaluation, and Management of Intracranial Vascular Malformations
Mayo Clin. Proc., February 1, 2005; 80(2): 269 - 281.
[Abstract] [PDF]


Home page
StrokeHome page
R. Al-Shahi, J. J. Bhattacharya, D. G. Currie, V. Papanastassiou, V. Ritchie, R. C. Roberts, R. J. Sellar, and C. P. Warlow
Scottish Intracranial Vascular Malformation Study (SIVMS): Evaluation of Methods, ICD-10 Coding, and Potential Sources of Bias in a Prospective, Population-Based Cohort
Stroke, May 1, 2003; 34(5): 1156 - 1162.
[Abstract] [Full Text] [PDF]